Perfluorocarbon liquids are frequently used intraoperatively in repair of complicated retinal detachments. One complication of their use is prfluorocarbon liquids entering the subretinal space via a retinal break or an iatrogenic retmotomy since these liquids are much heavier than water, We evaluated the response to subretinal perfluorophenanthrene (VitreonR) on the rabbit retina ophthalmoscopically and microscopically. Twenty eight rabbit eyes underwent subretinal injection of 50-100 ml of perfluorophenanthrene via the vitreous space. The same volume of balanced salt solution was injected into control eyes. Eyes were monitored by indirect ophthalmoscopy and examined by light and electron microscopy. Progressive retinal detachments with newly formed retinal breaks in the inferior quadrants developed in 24 of 28 eyes. In the remaining 4 eyes, small retinal bleb, from 0.5 to 3DD size, occurred in inferior peripheral retina. The photoreceptor outer and inner segments were lost and receptor cell nuclei began to deplete within 1-3 days. In addition, marked vacuole formation in the retinal fiber layers as well as in inner and outer nuclear layers were seen. The photoreceptor outer and inner segments had a1most dlsappeared and the number of nuclei in irulei and outer nuclear layers was markedly decreased from 1 to 3 months. The control eyes reattached and healed spontaneously within 3-5 days. Our findings suggest that all subretinal perfluorophenanthrene should be carefully removed from the eyes at the end of the surgery.
Blister ; Cell Nucleus ; Microscopy, Electron ; Ophthalmoscopy ; Retina ; Retinal Detachment ; Retinal Perforations ; Retinaldehyde* ; Vacuoles

Perfluorocarbon liquids are frequently used intraoperatively in repair of complicated retinal detachments. One complication of their use is prfluorocarbon liquids entering the subretinal space via a retinal break or an iatrogenic retmotomy since these liquids are much heavier than water, We evaluated the response to subretinal perfluorophenanthrene (VitreonR) on the rabbit retina ophthalmoscopically and microscopically. Twenty eight rabbit eyes underwent subretinal injection of 50-100 ml of perfluorophenanthrene via the vitreous space. The same volume of balanced salt solution was injected into control eyes. Eyes were monitored by indirect ophthalmoscopy and examined by light and electron microscopy. Progressive retinal detachments with newly formed retinal breaks in the inferior quadrants developed in 24 of 28 eyes. In the remaining 4 eyes, small retinal bleb, from 0.5 to 3DD size, occurred in inferior peripheral retina. The photoreceptor outer and inner segments were lost and receptor cell nuclei began to deplete within 1-3 days. In addition, marked vacuole formation in the retinal fiber layers as well as in inner and outer nuclear layers were seen. The photoreceptor outer and inner segments had a1most dlsappeared and the number of nuclei in irulei and outer nuclear layers was markedly decreased from 1 to 3 months. The control eyes reattached and healed spontaneously within 3-5 days. Our findings suggest that all subretinal perfluorophenanthrene should be carefully removed from the eyes at the end of the surgery.
Blister ; Cell Nucleus ; Microscopy, Electron ; Ophthalmoscopy ; Retina ; Retinal Detachment ; Retinal Perforations ; Retinaldehyde* ; Vacuoles

PURPOSE: To differentiate the genes that are up-regulated or down-regulated and the cellular morphology in the corneal stromal cells between normal and diabetic rat. METHODS: After isolation with trizol (GIBCO, NY, USA), labeling and purification of complementary DNA(cDNA) probes were carried out using Atlas(TM) Glass Microarrays 1.0. RESULTS: Autoradiographic analysis showed that 35 genes were up-regulated and 8 genes were down-regulated by Atlas Image(TM) Software. Up-regulated genes were as calcium/calmodulin dependent protein kinase I, proteasome 26S subunit 1, prostaglandin F receptor. Down-regulated genes were aquaporin 8, cytochrome c oxidase polypeptide Vb, glypican 1. CONCLUSIONS: There were many differential genes in hormone receptor, voltage gated ion channels, oncogenes and tumor suppressors, G protein between normal and diabetic keratocyte of rat.
Animals ; Cornea* ; Electron Transport Complex IV ; Glass ; Glypicans ; GTP-Binding Proteins ; Ion Channels ; Oncogenes ; Proteasome Endopeptidase Complex ; Protein Kinases ; Rats* ; Stromal Cells

Naringenin (NAR) as one of the flavonoids observed in grapefruit has been reported to exhibit an anti-cancer activity. However, more detailed mechanism by which NAR exerts anti-cancer properties still remains unanswered. Thus, in this study, we have shown that NAR down-regulates the level of cyclin D1 in human colorectal cancer cell lines, HCT116 and SW480. NAR inhibited the cell proliferation in HCT116 and SW480 cells and decreased the level of cyclin D1 protein. Inhibition of proteasomal degradation by MG132 blocked NAR-mediated cyclin D1 downregulation and the half-life of cyclin D1 was decreased in the cells treated with NAR. In addition, NAR increased the phosphorylation of cyclin D1 at threonine-286 and a point mutation of threonine-286 to alanine blocked cyclin D1 downregulation by NAR. p38 inactivation attenuated cyclin D1 downregulation by NAR. From these results, we suggest that NAR-mediated cyclin D1 downregulation may result from proteasomal degradation through p38 activation. The current study provides new mechanistic link between NAR, cyclin D1 downregulation and cell growth in human colorectal cancer cells.
Alanine ; Cell Line ; Cell Proliferation ; Citrus paradisi ; Colorectal Neoplasms* ; Cyclin D1* ; Down-Regulation* ; Flavonoids ; Half-Life ; Humans ; Phosphorylation ; Point Mutation

Background: To deliver therapeutics into the brain, it is imperative to overcome the issue of the blood-brain-barrier (BBB). One of the ways to circumvent the BBB is to administer therapeutics directly into the brain parenchyma. To enhance the treatment efficacy for chronic neurodegenerative disorders, repeated administration to the target location is required. However, this increases the number of operations that must be performed. In this study, we developed the IntraBrain Injector (IBI), a new implantable device to repeatedly deliver therapeutics into the brain parenchyma. Methods: We designed and fabricated IBI with medical grade materials, and evaluated the efficacy and safety of IBI in 9 beagles. The trajectory of IBI to the hippocampus was simulated prior to surgery and the device was implanted using 3D-printed adaptor and surgical guides. Ferumoxytol-labeled mesenchymal stem cells (MSCs) were injected into the hippocampus via IBI, and magnetic resonance images were taken before and after the administration to analyze the accuracy of repeated injection. Results: We compared the planned vs. insertion trajectory of IBI to the hippocampus.With a similarity of 0.990 ± 0.001 (mean ± standard deviation), precise targeting of IBI was confirmed by comparing planned vs. insertion trajectories of IBI. Multiple administrations of ferumoxytol-labeled MSCs into the hippocampus using IBI were both feasible and successful (success rate of 76.7%). Safety of initial IBI implantation, repeated administration of therapeutics, and long-term implantation have all been evaluated in this study. Conclusion Precise and repeated delivery of therapeutics into the brain parenchyma can be done without performing additional surgeries via IBI implantation.